OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review

Simple item page
dc.coverageDOI: 10.2147/BTT.S511125
dc.creatorValenzuela, Fernando
dc.creatorMeza, Victor
dc.date2025
dc.date.accessioned2025-11-18T19:52:55Z
dc.date.available2025-11-18T19:52:55Z
dc.description<p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease, whose pathophysiology involves a complex interplay of genetic and environmental factors that lead to dysregulated T-cell-mediated inflammatory pathways and a compromised skin barrier. Despite the recent introduction of novel targeted therapies for moderate-to-severe AD, many patients still fail to achieve or maintain treatment goals, or experience treatment-emergent adverse events, which continue to burden their disease management. Recently, the role of T cell co-stimulatory molecule OX40 and its ligand OX40L, which is mainly expressed on professional antigen-presenting cells such as dendritic cells, has attracted widespread research attention as a potential therapeutic target in T cell-mediated skin diseases. Moreover, early basic and clinical research has shown encouraging results regarding the efficacy and safety of therapies targeting the OX40-OX40L axis in moderate-to-severe AD. Therefore, herein we aim to summarize the current evidence regarding the efficacy and safety of inhibiting the OX40/OX40L signaling axis in patients with moderate-to-severe AD.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/3e9b5acb-c0e9-41d4-8af4-2f1e3fe29c6e
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/57978
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.19 (2025) p.281-288
dc.subjectamlitelimab
dc.subjectatopic dermatitis
dc.subjecteczema
dc.subjectOX40
dc.subjectOX40L
dc.subjectrocatinlimab
dc.subjecttargeted therapies
dc.subjecttelazorlimab
dc.titleOX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Revieweng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE